B‐lymphocyte suppression in multiple myeloma is a reversible phenomenon specific to normal B‐cell progenitors and plasma cell precursors-Reference-Cited by-同舟云学术

B‐lymphocyte suppression in multiple myeloma is a reversible phenomenon specific to normal B‐cell progenitors and plasma cell precursors

Published:1998-01 Issue:1 Volume:100 Page:176-183
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:British Journal of Haematology

Author:

Rawstron Andrew C.¹,Davies Faith E.¹,Owen Roger G.¹,English Anne¹,Pratt Guy¹,Child J. Anthony¹,Jack Andrew S.¹,Morgan Gareth J.¹

Affiliation:

1. Department of Haematology, The General Infirmary at Leeds, Leeds

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1365-2141.1998.00525.x

Reference30 articles.

1. Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B cell

2. CD34+ circulating B cells in multiple myeloma have a rearranged IgH VDJ identical to that of autologous plasma cells as quantitated by in‐situ RT‐PCR;Belch A.R.;Blood,1996

3. In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain;Bergsagel P.L.;Blood,1995

4. The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell.

5. Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients;Billadeau D.;Blood,1992

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Examining the immunological responses to COVID-19 vaccination in multiple myeloma patients: a systematic review and meta-analysis;BMC Geriatrics;2024-05-08

2. Educational Case: Multiple myeloma;Academic Pathology;2024-04

3. Definers and drivers of functional high-risk multiple myeloma: insights from genomic, transcriptomic, and immune profiling;Frontiers in Oncology;2023-10-02

4. Multi-omics investigation of the resistance mechanisms of pomalidomide in multiple myeloma;Frontiers in Oncology;2023-09-19

5. Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial;British Journal of Haematology;2023-09-10